Management of Cutaneous Lupus Erythematosus with JAK Inhibitor Therapy: An Evidence-Based Review

Cutaneous lupus erythematosus (CLE) is a rare, isolated form of lupus erythematosus localized to the skin. CLE results in a wide variety of dermatologic manifestations. With no FDA-approved treatments for CLE, initial treatment typically involves topical and systemic corticosteroids. The use of Janus kinase inhibitors (JAKi) for CLE remains novel. This systematic review examines the literature and summarizes the effectiveness and safety outcomes of JAKi therapies in treating CLE.

皮肤红斑狼疮（Cutaneous lupus erythematosus, CLE）是一种罕见的、仅局限于皮肤的孤立性红斑狼疮类型。该疾病可表现为多样的皮肤临床症状。目前尚无美国食品药品监督管理局（Food and Drug Administration, FDA）获批的CLE治疗方案，临床初始治疗通常采用外用及系统性糖皮质激素。Janus激酶抑制剂（Janus kinase inhibitors, JAKi）用于CLE治疗的相关应用仍属新兴研究方向。本系统综述梳理现有相关文献，总结了JAKi疗法治疗CLE的有效性与安全性结局。